Literature DB >> 20810680

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Elena Fragapane1, Roberto Gasparini, Francesco Schioppa, Franco Laghi-Pasini, Emanuele Montomoli, Angelika Banzhoff.   

Abstract

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20810680      PMCID： PMC2976095          DOI： 10.1128/CVI.00461-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  10 in total

1.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Authors:  Iain Stephenson; Karl G Nicholson; Anthony Colegate; Audino Podda; John Wood; Ellen Ypma; Maria Zambon
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

2.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Authors:  Robert L Atmar; Wendy A Keitel; Shital M Patel; Jacqueline M Katz; Dewei She; Hana El Sahly; Justine Pompey; Thomas R Cate; Robert B Couch
Journal:  Clin Infect Dis       Date:  2006-09-25       Impact factor: 9.079

Review 3.  The risk of seasonal and pandemic influenza: prospects for control.

Authors:  Arnold S Monto
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

4.  Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.

Authors:  Jiang-Tao Lin; Chang-Gui Li; Xu Wang; Nan Su; Yan Liu; Yuan-Zheng Qiu; Meng Yang; Jiang-Ting Chen; Han-Hua Fang; Xiao-Ping Dong; Wei-Dong Yin; Zi-Jian Feng
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

5.  Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

Authors:  Terry M Nolan; Peter C Richmond; Maryanne V Skeljo; Georgina Pearce; Gunter Hartel; Neil T Formica; Katja Höschler; Jillian Bennet; David Ryan; Kelly Papanaoum; Russell L Basser; Maria C Zambon
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

6.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Authors:  Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

7.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

8.  Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

Authors:  Lance C Jennings; Arnold S Monto; Paul K S Chan; Thomas D Szucs; Karl G Nicholson
Journal:  Lancet Infect Dis       Date:  2008-10       Impact factor: 25.071

9.  MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.

Authors:  Angelika Banzhoff; Roberto Gasparini; Franco Laghi-Pasini; Tommaso Staniscia; Paolo Durando; Emanuele Montomoli; Pier Leopoldo Capecchi; Pamela Capecchi; Pamela di Giovanni; Laura Sticchi; Chiara Gentile; Anke Hilbert; Volker Brauer; Sandrine Tilman; Audino Podda
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

Review 10.  MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Authors:  Angelika Banzhoff; Michele Pellegrini; Giuseppe Del Giudice; Elena Fragapane; Nicola Groth; Audino Podda
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380
  10 in total
  17 in total

1.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

Review 2.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 3.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

4.  A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Authors:  Karl-Heinz Herbinger; Frank von Sonnenburg; Hans Dieter Nothdurft; Pamela Perona; Astrid Borkowski; Elena Fragapane; Uwe Nicolay; Ralf Clemens
Journal:  Hum Vaccin Immunother       Date:  2013-09-20       Impact factor: 3.452

5.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

6.  Inflammatory responses to influenza vaccination at the extremes of age.

Authors:  Jacqueline U McDonald; Ziyun Zhong; Helen T Groves; John S Tregoning
Journal:  Immunology       Date:  2017-05-16       Impact factor: 7.397

7.  Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.

Authors:  Pio Lopez; Yolanda Caicedo; Alexandra Sierra; Sandrine Tilman; Ralf Clemens; Angelika Banzhoff
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

Review 8.  Vaccine strategies to enhance immune responses in the aged.

Authors:  Julie S Lefebvre; Laura Haynes
Journal:  Curr Opin Immunol       Date:  2013-06-10       Impact factor: 7.486

9.  Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Authors:  Iván Bihari; Gyula Pánczél; Jozsef Kovacs; Jenny Beygo; Elena Fragapane
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

10.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.